A multi-centre study by Jorge et al. highlighted the cardiac and renal benefits of SGLT2 inhibitors in SLE and lupus nephritis patients, emphasising reduced risks of major cardiovascular events and renal progression. This evidence concerns the gene SLC5A2 and systemic lupus erythematosus.